Sugi Predict

Sugi Predict / Compounds / Arginine

Arginine

Arginine

SCHEMBL1930648

CC(C)C[C@H](N)C(=O)O.CC(C)[C@H](N)C(=O)O.CC[C@H](C)[C@H](N)C(=O)OC(=O)[C@@H](N)[C@@H](C)OC(=O)[C@@H](N)CC(N)=O.C[C@H](N)C(=O)O.C[C@H](N)C(=O)O.N=C(N)NCCC[C@H](N)C(=O)O.N=C(N)NCCC[C@H](N)C(=O)O.NC(=O)CC[C@H](N)C(=O)OC[C@H](N)C(=O)O.N[C@@H](CC(=O)O)C(=O)O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL8084582 0.82 NPY4R (0.37) —
Aspartic Acid SCHEMBL11135113 0.82 — —
Arginine SCHEMBL6140344 0.81 KLK7 (0.30) —
Glutamine SCHEMBL7514526 0.79 KEAP1 (0.30) —
Arginine SCHEMBL5063567 0.78 NPY4R (0.35) —
Valine SCHEMBL10883242 0.78 — —
Glutamine SCHEMBL4300953 0.76 ALOX15 (0.40) —
Arginine SCHEMBL9551434 0.75 GSR (0.37) —
Glutamine SCHEMBL8204628 0.75 NPY4R (0.33) —
Arginine SCHEMBL16679102 0.75 SLC7A5 (0.41) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7955845-B2 Transgenic cells comprising enhanced immune response for use in treatment of infections, cancers and pathologies associated with transplantation DANA FARBER CANCER INSTITUTE, INC. (US) 2011-06-07 — — US disclosed
EP-1769066-A4 MODIFIED ANTIGEN-PRESENTING CELLS DANA FARBER CANCER INST INC (US) 2008-08-13 — — EP disclosed
EP-1769066-A2 MODIFIED ANTIGEN-PRESENTING CELLS DANA-FARBER CANCER INSTITUTE (US) 2007-04-04 — — EP disclosed
WO-2005113589-A2 MODIFIED ANTIGEN-PRESENTING CELLS DANA-FARBER CANCER INSTITUTE (US) 2005-12-01 — — WO disclosed
EP-1458241-A4 MODIFIED ANTIGEN-PRESENTING CELLS DANA FARBER CANCER INST INC (US) 2005-11-09 — — EP disclosed
US-20050003484-A1 Modified antigen-presenting cells DANA FARBER CANCER INSTITUTE 2005-01-06 — — US disclosed
EP-1458241-A2 MODIFIED ANTIGEN-PRESENTING CELLS DANA-FARBER CANCER INSTITUTE (US) 2004-09-22 — — EP disclosed
WO-2003065977-A9 MODIFIED ANTIGEN-PRESENTING CELLS DANA FARBER CANCER INST INC (US) 2003-10-16 — — WO disclosed
WO-2003065977-A2 MODIFIED ANTIGEN-PRESENTING CELLS DANA-FARBER CANCER INSTITUTE (US) 2003-08-14 — — WO disclosed
US-5651993-A IRRADIATING LEUKOCYTE MIXTURE IN PSORALEN PRESENCE; REACTING WITH PEPTIDE ANTIGENS YALE UNIVERSITY (US) 1997-07-29 — — US disclosed